C5a anaphylatoxin is a major regulator of activating versus inhibitory Fc gamma Rs in immune complex-induced lung disease

2002 | journal article. A publication with affiliation to the University of Göttingen.

Jump to:Cite & Linked | Documents & Media | Details | Version history

Cite this publication

​C5a anaphylatoxin is a major regulator of activating versus inhibitory Fc gamma Rs in immune complex-induced lung disease​
Shushakova, N.; Skokowa, J.; Schulman, J.; Baumann, U.; Zwirner, J.; Schmidt, R. E. & Gessner, J. E.​ (2002) 
Journal of Clinical Investigation110(12) pp. 1823​-1830​.​ DOI: https://doi.org/10.1172/JCI200216577 

Documents & Media

License

GRO License GRO License

Details

Authors
Shushakova, N.; Skokowa, J.; Schulman, J.; Baumann, U.; Zwirner, Joerg; Schmidt, R. E.; Gessner, J. E.
Abstract
IgG Fc receptors (FcgammaRs, especially FcgammaRIII) and complement (in particular, C5a anaphylatoxin) are critical effectors of the acute inflammatory response to immune complexes (ICs). However, it is unknown whether and how these two key components can interact with each other in vivo. We use here a mouse model of the acute pulmonary IC hypersensitivity reaction to analyze their potential interaction. FcgammaRIII and C5aR are coexpressed on alveolar macrophages (AMs), and both FcgammaRIII and C5aR mutant mice display impaired immune responses. We find that recombinant human C5a (rhC5a) can control inverse expression of various FcgammaRs, and costimulation of ICs with rhC5a results in strong enhancement of FcgammaRIII-triggered cellular activation in vitro and in vivo. Moreover, we show here that early IC-induced bioactive C5a, and its interaction with C5aR, causes induction of activating FcgammaRIII and suppression of inhibitory FcgammaRII on AMs that appears crucial for efficient cytokine production and neutrophil recruitment in lung pathology. Therefore, C5a, which is a potent chemoattractant, has a broader critical function in regulating the inhibitory/activating FcgammaRII/III receptor pair to connect complement and FcgammaR effector pathways in immune inflammation.
Issue Date
2002
Status
published
Publisher
Amer Soc Clinical Investigation Inc
Journal
Journal of Clinical Investigation 
ISSN
0021-9738

Reference

Citations


Social Media